Calmer Co International Limited · ASX:CCO
Calmer Co International — Investor Presentation (July 2021)
23 slides from Calmer Co International's investor presentation, Jul 8, 2021
Slide 1: Fiji Kava | Welcome to Fijiness
Slide 2: Disclaimer
DISCLAIMER This presentation and any Materials provided (materials) have been prepared by Fiji Kava Limited (Fiji Kava) and contain general information about Fiji Kava activities. By accepting the Materials and attending the Fiji Kava presentation, you agree to be bound by the below terms and condit
Slide 3: Executive Summary
EXECUTIVE SUMMARY INVESTOR UPDATE JULY 2021 STRONG SALES GROWTH IN FY21 BROADENING BASE OF DEMAND INTERNATIONALLY INVENTORY BUILT UP FOR FY22 GROWTH STRESS, ANXIETY AND SLEEP MARKET OPPORTUNITY SUPPLY CHAIN EXCELLENCE GROWING AVAILABILITY OF NOBLE FIJIAN KAVA INNOVATION AND NEW PRODUCT DEVELOPMENT G
Slide 4: Fiji Kava [ASX:FIJ]
FIJI KAVA [ASX:FIJ] NOBLE KAVA SUPPLY CHAIN EXCELLENCE MEDICINAL KAVA HEALTH & GROWING AVAILABILITY OF FIJIAN NOBLE KAVA WELLNESS COMPANY WHICH PRODUCES NATURAL ‘NOBLE KAVA’ PRODUCTS INNOVATION & PRODUCT DEVELOPMENT FOR THE COMPLEMENTARY AND ALTERNATIVE PROMOTE THE MEDICINE MARKET MEDICINAL BENEFITS
Slide 5: Strong Sales Growth Despite a Challenging Environment
STRONG SALES GROWTH DESPITE A CHALLENGING ENVIRONMENT FIJI KAVA HAS DELIVERED >65% REVENUE GROWTH IN FY21 VS FY20 KEY HIGHLIGHTS $ REVENUE 000’s $1,400 Record annual revenue result > $1,2M achieved in FY21 An increase of >65% versus prior year continuing the growth trajectory $1,200 Q4 FY21 cash rec
Slide 6: Broad Base of Demand
BROAD BASE OF DEMAND SALES ARE GROWING IN CAPSULES, POWDERS AND INGREDIENTS IN AUSTRALIA, USA AND CHINA 4% 17% 38% 11% 48% 1% 67% 14% Fiji Aus NZ China USA Ingredients Powder Capsules
Slide 7: Fiji Kava Remains in Production Throughout the COVID Pandemic
FIJI KAVA REMAINS IN PRODUCTION THROUGHOUT THE COVID PANDEMIC AND HAS BUILD INVENTORY TO SUPPORT THE GROWTH EXPECTED IN FY22 Inventory Build STATUS TO DATE DURING PANDEMIC Approx. value at COGs pending stocktake $1,600 Fiji Kava has continued to operate both in Fiji and abroad during the $1,400 COVI
Slide 8: Stress & Anxiety Growing Globally
STRESS & ANXIETY GROWING GLOBALLY
Slide 9: Global Marketplace
GLOBAL MARKETPLACE THE CURRENT GLOBAL CORONAVIRUS PANDEMIC, SUPPORTS THE PROJECTED GROWTH OF THE KAVA EXTRACT MARKET GLOBALLY TO USD $774M KEY DATA Consumer health spending globally in 2020 is estimated at over $270B with growth forecast at 2.1% YOY to 20252 USD $115 billion Global Vitamin and Dieta
Slide 10: Noble Kava Supply Chain Excellence
Slide 11: Vertically Integrated Supply Chain Remains a Key Competitive Advantage
FIJI KAVA VERTICALLY INTEGRATED SUPPLY CHAIN REMAINS A KEY COMPETITIVE ADVANTAGE We are the first and only foreign company with approval from the Fijian government to operate in the Noble Kava industry Fiji Kava is focused on only cultivars that are of ‘Noble’ variety – a safe and medicinally superi
Slide 12: Fiji Grower Network
FIJI GROWER NETWORK WE CONTINUE TO RAISE THE STANDARD AND CAPABILITY OF OUR GROWING PARTNERS SELECTED BASED ON KEY CRITERIA INCLUDING Grow and supply preferred varieties specifications Historical geographical kavalactone (active API) data Agronomic Practices for sustainable production and GAP Nurser
Slide 13: Noble Kava
NOBLE KAVA
Slide 14: Markets & Channels
MARKETS & CHANNELS OUR KEY INTERNATIONAL ROUTE TO MARKETS ARE CLEARLY DEFINED CHANNELS TO MARKET Pharmacy / Drug Store Grocery / Supermarkets eCommerce & Affiliates Complimentary Healthcare Specialty Ingredients KEY MARKETS Fiji Australia & NZ United States China
Slide 15: Strong Progress With Availability of Noble Kava Capsules and Powders
STRONG PROGRESS HAS BEEN MADE WITH AVAILABILITY OF FIJI KAVA’S NOBLE KAVA CAPSULES AND POWDERS Existing ranging in leading Australian & New Zealand retailers, including Green Cross NZ and Coles Supermarkets Chemist Warehouse now ranges the full suite of Noble Kava™ 60 vegan capsules in Australia and
Slide 16: We Continue to Build Ingredient Partnerships
WE CONTINUE TO BUILD INGREDIENT PARTNERSHIPS WITH LEADING VITAMIN AND DIETARY SUPPLEMENT BRANDS AND MANUFACTURERS KEY HIGHLIGHTS Agreement with Blackmores [ASX: BKL] owned BioCeuticals, to co- brand clinical product ‘AnxioCalm for Australia and New Zealand [INSERT showing above expected sales and co
Slide 17: Innovation & Product Development
Slide 18: Continued Innovation in Products and Formats
CONTINUED INNOVATION IN PRODUCTS AND FORMATS 'Sleep’, Calm’ & 'Body’ products launched in FY20 FY22 Innovations planned include; Fiji Kava Noble Night (Men) Fiji Kava Noble Night (Women) Fiji Kava Noble Focus Fiji Kava Noble Kava Extract (Forte) Fiji Kava Tea range (Immune, Calm and Sleep) Our growi
Slide 19: Medicinal Benefits
Slide 20: Fiji Kava Continues to Drive Awareness of Fijian Noble Kava
FIJI KAVA CONTINUES TO DRIVE AWARENESS OF FIJIAN NOBLE KAVA TO SUPPORT GROWTH THROUGH MARKETING INITIATIVES KEY HIGHLIGHTS Targeted promotional & display activities with retailers to showcase and build the brand awareness Social media relaunch resulting in >1m organic impressions & audience growth v
Slide 21: Specialty Ingredients (B2B)
SPECIALTY INGREDIENTS (B2B) EDUCATE LEADING VITAMIN AND DIETARY SUPPLEMENT BRANDS AND MANUFACTURERS ON THE EFFICACY OF FIJIAN NOBLE KAVA KEY HIGHLIGHTS Online Portal Evidence Packages Research Reports Health Segments Product Literature Specification Marketing Materials
Slide 22: Fiji Kava [ASX:FIJ]
NOBLE KAVA SUPPLY FIJI KAVA [ASX:FIJ] CHAIN EXCELLENCE GROWING AVAILABILITY OF FIJIAN NOBLE KAVA WE WILL CONTINUE TO FOCUS ON OUR KEY INNOVATION & PRODUCT STRATEGIC DRIVERS TO DEVELOPMENT DELIVER MEASURED AND SUSTAINABLE GROWTH PROMOTE THE MEDICINAL BENEFITS OF NOBLE KAVA
Slide 23: Investor Roadshow (November 2019)
Investor Roadshow (November 2019)qA89999999JKLM,
Calmer Co International — Investor Presentation (July 2021) on 6ix